Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS siRNA-NP
- Development stage
- Preclinical
- Lead developer
- Washington University in St. Louis
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
KRAS siRNA-NP is a preclinical therapeutic candidate consisting of small-interfering RNA (siRNA) targeting the KRAS oncogene, encapsulated within serum-stable, cell-penetrating, and endosomolytic peptide-based nanoparticles. Developed by researchers at Washington University in St. Louis, this delivery platform is designed to overcome the traditional limitations of siRNA, such as short circulating half-life and poor cellular uptake. By specifically downregulating KRAS expression, the drug aims to inhibit tumor growth in KRAS-driven malignancies, including pancreatic and colorectal cancers. Preclinical studies in mouse models have demonstrated significant reduction in tumor volume with twice-weekly intravenous administration, showing efficient uptake by tumor cells and minimal toxicity to the liver and kidneys.
- Other names
- KRAS-siRNA NPpeptide-based nanoparticles delivering KRAS siRNA
02
Targets
Kirsten rat sarcoma viral oncogene homolog mRNA
Beyond the preview
Go deeper on KRAS siRNA-NP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS siRNA-NP.